Hyperkalemia Pathophysiology, ECG Changes & Treatment Explained

Electrolyte disturbances significantly alter cardiac electrical activity, with potassium, calcium, and magnesium imbalances producing characteristic ECG changes: hyperkalemia causes tall peaked T waves, widened QRS, and shortened QT interval, while hypokalemia produces U waves, ST depression, and prolonged QT; hypercalcemia shortens QT interval, hypocalcemia prolongs it, and hypomagnesemia increases torsades de pointes risk; QT interval prolongation (>440ms in men, >460ms in women) indicates elevated risk of life-threatening ventricular arrhythmias.

Electrolyte imbalances significantly alter cardiac electrical activity and produce characteristic ECG changes: hypercalcemia shortens the QT interval, hypocalcemia prolongs it, hyperkalemia causes peaked T waves and widened QRS complexes, and hypokalemia produces flattened T waves with prominent U waves; these disturbances can lead to serious arrhythmias including ventricular tachycardia with torsades de pointes and cardiac arrest.

Electrolyte imbalances affect cardiac action potential phases and produce characteristic ECG changes: hypercalcemia shortens the QT interval by accelerating phase 2 (plateau phase), while hypocalcemia prolongs it; hyperkalemia causes progressive changes from peaked T-waves to sine wave patterns as potassium levels increase, whereas hypokalemia produces prominent U-waves, prolonged QT interval, and flattened T-waves; magnesium abnormalities show ECG changes similar to potassium disturbances; sodium abnormalities rarely cause significant ECG changes.

Electrolyte imbalances produce characteristic EKG changes and clinical manifestations. Hyperkalemia progresses from peaked T-waves to widened QRS to sine wave pattern, requiring calcium gluconate stabilization and potassium repletion. Hypokalemia (<3.5mEq/L) causes flattened T-waves, U-waves, arrhythmias, and ST depression; hypomagnesemia is the leading cause and must be corrected first. Hypocalcemia causes prolonged QT and Chvostek/Trousseau signs; hypercalcemia causes short QT. Ion channel mechanisms explain these effects: calcium blocks sodium channels (hypercalcemia causes hypoexcitability, hypocalcemia causes hyperexcitability).

Electrolyte imbalances significantly affect ECG patterns. In hypercalcemia (elevated calcium), the QT interval shortens because calcium enters the cell more quickly during the plateau phase, shortening the plateau and thus the QT interval. The ST segment and PR interval also shorten. In hypocalcemia (low calcium), the opposite occurs: the QT interval prolongs because calcium enters the cell more slowly, lengthening the plateau phase. The instructor emphasizes that these changes are critical diagnostic features for identifying electrolyte disturbances. The instructor also explains that the U wave (representing repolarization of Purkinje fibers) becomes prominent in hypocalcemia.

Acute hyperkalemia treatment follows a priority-based protocol: (1) Calcium gluconate 10 mL 10% IV over 10 minutes stabilizes cardiac membranes and prevents arrhythmias (works within 1-3 minutes); (2) Insulin 10 units IV with 25% glucose 100 mL drives potassium into cells (works within 30 minutes, lasts 3-4 hours); (3) Beta-2 agonists (albuterol) shift potassium into cells (works within 30 minutes); (4) Potassium binders (sodium polystyrene sulfonate, patiromer, sodium zirconium cyclosilicate) remove potassium through GI tract (Lokelma works within 1 hour). Calcium gluconate must be given first for cardiac protection before other treatments.

Hyperkalemia treatment involves two approaches: stabilizing/redistributing potassium and promoting excretion. Calcium gluconate (1-3g IV over 10 min) or calcium chloride stabilizes cardiac membranes first. Insulin (5 units for renal patients, 10 units otherwise) with dextrose shifts potassium intracellularly. Bicarbonate drives potassium back into cells. Dialysis removes potassium for renal patients. Lasix is ineffective without urine output. Albuterol and potassium binders take hours to work.

Hyperkalemia (serum potassium >6.5 mmol/L) requires urgent emergency treatment including calcium gluconate or chloride to stabilize the myocardium, followed by intracellular potassium shift using salbutamol (beta agonist nebulizer) and insulin with dextrose to prevent hypoglycemia; however, these are temporary measures requiring ongoing monitoring and definitive treatment of the underlying cause such as stopping potassium-wasting medications or reversing acute kidney injury, with dialysis reserved for refractory cases.

For hyperkalemia (potassium >6.5 mEq/L or with ECG changes), three immediate steps are essential: (1) Protect the heart using intravenous calcium gluconate (10% solution diluted in 50-100mL saline or glucose), which stabilizes cardiac membranes; (2) Shift potassium into cells using insulin with glucose, beta-2 agonists, or other agents; (3) Eliminate potassium through diuretics (furosemide) or dialysis in severe cases. This systematic approach provides time for definitive treatment while protecting the heart.

Emergency treatment for hyperkalemia with potassium above 6.5 mmol/L or ECG changes includes: IV calcium gluconate (10 ml of 10% solution over 10 minutes) to stabilize cardiac membrane, IV insulin with glucose (10 units regular insulin with 25-50g glucose) to shift potassium into cells, and beta-agonists (salbutamol nebulization) to shift potassium into cells. Calcium gluconate does not lower potassium but prevents arrhythmias. After stabilization, potassium must be shifted into cells and removed from the body. Insulin-glucose therapy shifts potassium into cells. Beta-agonists and sodium bicarbonate (50-200 ml) also shift potassium into cells. Loop diuretics (furosemide) promote potassium excretion. Kayexalate (sodium polystyrene sulfonate) binds potassium in the GI tract. Dialysis is used for refractory cases with severe renal impairment.

Chronic hyperkalemia, particularly in patients with chronic kidney disease (CKD) and those on RAAS inhibitors, requires effective long-term management strategies. Traditional approaches include removing modifiable causes, using diuretics, dietary potassium restriction, and dialysis, but each carries limitations. Novel oral potassium-binding agents—patiromer (a cation-exchange polymer) and zirconium cyclosilicate (an inorganic compound)—represent significant advances by binding potassium in the gastrointestinal tract in exchange for hydrogen and sodium, thereby increasing fecal potassium excretion. These agents allow continued or even escalated RAAS inhibitor therapy while maintaining potassium control, addressing the critical need for safe, effective, and well-tolerated treatments for patients at high risk of hyperkalemia.

Managing hyperkalemia in CKD patients requires a multifaceted approach. First, assess kidney function to define hyperkalemia risk and discontinue drugs interfering with potassium secretion, including NSAIDs and herbal preparations which are often adulterated. Select appropriate diuretics: thiazides or loop diuretics for eGFR <30 mL/min to facilitate potassium excretion. Sodium bicarbonate corrects acidosis, which ameliorates hyperkalemia. Newer potassium binding agents (patiromer, sodium zirconium cyclosilicate) enable continued RAS inhibitor use. When initiating or increasing RAS inhibitors (ACEi, ARB, MRAs), measure potassium one week later; for increases up to 5.5 mEq/L, decrease drug dose; for combinations, discontinue one agent. Spironolactone should not exceed 25 mg daily with RAS inhibitors. When eGFR <30 mL/min, search for drug combinations and stop unnecessary medications.

Hyperkalemia is a major complication affecting up to 50% of cardiorenal patients with CKD and HF, with high recurrence rates (over 40% within 6-7 months) and significantly increased mortality, hospitalization risk, and healthcare costs (€4,500-12,000 annually). The condition creates a therapeutic dilemma because RAAS blockade, essential for cardiovascular and renal protection, inherently increases potassium levels. Effective management requires a systematic approach: confirm diagnosis by ruling out pseudohyperkalemia, classify severity, identify underlying causes (intake, redistribution, decreased excretion), and implement the four-pillar strategy. Traditional binders have poor tolerability and limited efficacy. New agents like patiramer and zavesca offer faster onset (hours vs. days), better tolerability, and superior efficacy in clinical trials, enabling optimal RAAS inhibitor titration in high-risk patients. Clinical guidelines recommend initiating binders in patients with potassium above 5.0 mEq/L on RAAS inhibitors, with weekly monitoring and SICK day rules for acute illness.

Effective hyperkalemia management in CKD patients requires systematic identification of high-risk individuals including those with elevated baseline creatinine, dehydration, heart failure, or renal artery stenosis. Before initiating RAS inhibitors, clinicians must rule out renal artery stenosis and avoid potassium-raising medications like spironolactone, triamterene, and NSAIDs. Dietary potassium restriction through limiting fruits is essential. Diuretics must be used judiciously—overuse increases hyperkalemia risk while underuse fails to control potassium. Regular monitoring of renal function and potassium levels is mandatory. New potassium-binding agents (patiromer, sodium zirconium cyclosilicate) offer safer alternatives to SPS for long-term management. Patients should be classified as low-risk (stable BP, normal potassium, stage 1-2 CKD, <15% eGFR drop) requiring 2-3 month monitoring intervals, or high-risk (low BP, low baseline eGFR, borderline potassium, >30% eGFR drop) requiring weekly or biweekly monitoring.

Hyperkalemia affects 30% of CKD patients (7% with potassium >6.0 mmol/L), with prevalence increasing due to population aging, polypharmacy, and widespread RAAS inhibitor use. Risk factors include declining renal function, hipoaldosteronism, cardiovascular disease, and medications (RAAS inhibitors, potassium-sparing diuretics, NSAIDs). Healthcare costs range from 6,000 euros (mild-moderate) to 12,700 euros (severe) annually per patient. Traditional management limitations include poor dietary adherence, RAAS inhibitor discontinuation eliminating mortality benefits, and potassium binder non-adherence (only 30% completed one year). A study of 205,000 patients demonstrated that RAAS inhibitor discontinuation significantly increases cardiovascular events and heart failure hospitalizations. The 2022 European Society of Cardiology guidelines recommend avoiding RAAS inhibitor discontinuation and considering new potassium binders with better tolerability. Zirconium cyclosilicate binds ammonium in the intestine, correcting hyperkalemia while also improving metabolic acidosis. Studies show 88% of patients maintained potassium <5.5 mmol/L over 12 months, with reduced mortality and hospitalizations compared to traditional binders.